Program
RBD5044
A development code.
Its studies are mostly in Dyslipidemias · Hypertriglyceridemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Ribo Life Science | 21 open or running | phase 2since Jan 22, 2025 | Aug 22, 2022 | May 31, 2027phase 2 · NCT06797401 |
| Ribotek Biopharmaceuticals (Shandong) | 11 open or running | phase 2since May 4, 2026 | May 4, 2026 | Mar 2027phase 2 · NCT07587788 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2022First study: phase 1 study in Health VolunteerNew to Suzhou Ribo Life ScienceSuzhou Ribo Life Science · NCT05539651 · 72 enrolled · Australia
- Jan 22, 2025Phase 2 study in DyslipidemiasSuzhou Ribo Life Science · NCT06797401 · 120 planned · Poland, Sweden
- May 4, 2026Ribotek Biopharmaceuticals (Shandong)'s first study: phase 2 study in HypertriglyceridemiaNew to Ribotek Biopharmaceuticals (Shandong)Ribotek Biopharmaceuticals (Shandong) · NCT07587788 · 40 enrolled · China
Ahead
- Mar 2027Primary completion: phase 2 study in HypertriglyceridemiaRibotek Biopharmaceuticals (Shandong) · NCT07587788
- May 31, 2027Primary completion: phase 2 study in DyslipidemiasSuzhou Ribo Life Science · NCT06797401
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07587788Hypertriglyceridemia · China | 2 | Active, not recruiting | Ribotek Biopharmaceuticals (Shandong) | Mar 2027 | 40 |
| NCT06797401Dyslipidemias · Poland, Sweden | 2 | Recruiting | Suzhou Ribo Life Science | May 31, 2027 | 120 |
| NCT05539651Health Volunteer · Australia | 1 | Completed | Suzhou Ribo Life Science | Oct 30, 2024 | 72 |
How it is read
Names in the registry
- “RBD5044”, 3 entries
Codes read as this program: RBD5044.
Conditions, from the studies’ own filings
- Dyslipidemias, 1 study
- Hypertriglyceridemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.